Literature DB >> 22072812

Bortezomib: understanding the mechanism of action.

Bilal Piperdi1, Yi-He Ling, Leonard Liebes, Franco Muggia, Roman Perez-Soler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22072812     DOI： 10.1158/1535-7163.MCT-11-0745

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN： 1535-7163            Impact factor:   6.261


× No keyword cloud information.
  20 in total

1.  Bortezomib induces neuropathic pain through protein kinase C-mediated activation of presynaptic NMDA receptors in the spinal cord.

Authors:  Jing-Dun Xie; Shao-Rui Chen; Hong Chen; Hui-Lin Pan
Journal:  Neuropharmacology       Date:  2017-06-27       Impact factor: 5.250

Review 2.  Thermal potentiation of chemotherapy by magnetic nanoparticles.

Authors:  Madeline Torres-Lugo; Carlos Rinaldi
Journal:  Nanomedicine (Lond)       Date:  2013-10       Impact factor: 5.307

3.  CCR 20th anniversary commentary: Preclinical study of proteasome inhibitor bortezomib in head and neck cancer.

Authors:  Clint T Allen; Barbara Conley; John B Sunwoo; Carter Van Waes
Journal:  Clin Cancer Res       Date:  2015-03-01       Impact factor: 12.531

Review 4.  NK cell-based immunotherapies in Pediatric Oncology.

Authors:  Kimberly A McDowell; Jacquelyn A Hank; Kenneth B DeSantes; Christian M Capitini; Mario Otto; Paul M Sondel
Journal:  J Pediatr Hematol Oncol       Date:  2015-03       Impact factor: 1.289

Review 5.  Proteasome inhibitors in cancer therapy.

Authors:  Elisabet E Manasanch; Robert Z Orlowski
Journal:  Nat Rev Clin Oncol       Date:  2017-01-24       Impact factor: 66.675

6.  Cluster Gauss-Newton and CellNOpt Parameter Estimation in a Small Protein Signaling Network of Vorinostat and Bortezomib Pharmacodynamics.

Authors:  Jin Niu; Van Anh Nguyen; Mohammad Ghasemi; Ting Chen; Donald E Mager
Journal:  AAPS J       Date:  2021-10-07       Impact factor: 3.603

Review 7.  Alterations in the E3 ligases Parkin and CHIP result in unique metabolic signaling defects and mitochondrial quality control issues.

Authors:  Britney N Lizama; Amy M Palubinsky; BethAnn McLaughlin
Journal:  Neurochem Int       Date:  2017-08-26       Impact factor: 3.921

Review 8.  A review of the application of inflammatory biomarkers in epidemiologic cancer research.

Authors:  Darren R Brenner; Dominique Scherer; Kenneth Muir; Joellen Schildkraut; Paolo Boffetta; Margaret R Spitz; Loic Le Marchand; Andrew T Chan; Ellen L Goode; Cornelia M Ulrich; Rayjean J Hung
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-06-24       Impact factor: 4.254

Review 9.  The mesenchymal tumor microenvironment: a drug-resistant niche.

Authors:  Edna Cukierman; Daniel E Bassi
Journal:  Cell Adh Migr       Date:  2012-05-01       Impact factor: 3.405

10.  Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib.

Authors:  Yinghao Zhao; Kun Zhang; Guangquan Li; Xingyi Zhang; Donglei Shi
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.